<DOC>
	<DOCNO>NCT02987504</DOCNO>
	<brief_summary>This multicenter , open-label , dose-escalation , Phase 1 study intravenous ( IV ) samalizumab determine maximum tolerate dose ( MTD ) , overall safety/tolerability , PK/pharmacodynamic parameter , efficacy patient advance solid tumor .</brief_summary>
	<brief_title>Study Samalizumab Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<criteria>1 . Male female patient ≥ 18 year age Screening . 2 . Eastern Cooperative Oncology Group performance status 02 . 3 . Patient advanced/metastatic cancer disease progression treatment available therapy know confer clinical benefit . 4 . Patient life expectancy great 12 week . 1 . Patient symptomatic brain metastasis . 2 . Patient active gastrointestinal bleeding evidence either hematemesis melena . 3 . Patient acute gastrointestinal ulcer . 4 . Patient history cancer present condition ( except nonmelanoma skin cancer carcinoma situ cervix ) , unless complete remission therapy disease minimum 3 year . 5 . Patient condition require systemic treatment either corticosteroid immunosuppressive medication within 14 day study drug administration . 6 . Patient active infection require therapy . 7 . Patient 's serum positive presence hepatitis B surface antigen ( HbsAg ) . antibody hepatitis C virus ( HCV ) , antibodies human immunodeficiency Virus 1/2 ( HIV 1/2 ) 8 . Patient significant cardiovascular impairment ( history New York Heart Association Functional Classification system Class III IV ) history myocardial infarction unstable angina within past 6 month prior study drug treatment . 9 . The patient 's recent test value within 14 day date entry meet following standard : Bone marrow function : neutrophil count ≤ 1500/mm3 , hemoglobin ≤ 9.0 g/dL , platelet count ≤ 100,000/mm3 . Liver function : total bilirubin ≥ 1.5 x upper limit normal ( ULN ) base standard value institution , aspartate aminotransferase alanine aminotransferase ≥ 2.5 x ULN base reference laboratory Renal function : serum creatinine ≥ 1.5 x ULN base reference laboratory 10 . Patient ongoing immunestimulated adverse event ( AEs ) immunotherapy ( eg , pneumonitis , thyroiditis , hepatitis ) history pneumonitis . 11 . Patient receive chemotherapy , target therapy , and/or immunotherapy within 28 day prior first dose study drug . 12 . Patient toxicity previous immunotherapy resolve Grade 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Solid tumor</keyword>
	<keyword>Phase 1</keyword>
</DOC>